Monday, December 20, 2021 12:57:10 UTC
With an emergency approval for use by the WHO, Novavax is ripping in premarket, and options have been historically adjusting very well for this stock.
The stock increased after World Health Organization granted the vaccine company and the Serum Institute of India an emergency use authorization for their Covid-19 vaccine.
Covovax, which is manufactured and marketed by the Serum Institute for India and other developing nations, has been awarded emergency use status by the WHO.
Novavax's Covid-19 vaccine is protein-based, unlike the vaccines developed by the Pfizer (PFE) and BioNTech (BNTX) alliance and Moderna (MRNA), which are based on messenger RNA drug technology.
NOTE: This is not an endorsement or rejection of vaccines. This is a stock market news item.(More)